Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹56.60down ₹1.33 (2.30%)BSE ₹58.36
Share price at the NSE close on 30 Oct 2026. Previous close ₹57.93.
30 Oct: open ₹56.60, high ₹58.49, low ₹56.33
52-week range of traded prices to 30 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹122 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,39760.1% delivered
Krebs Biochemicals and Industries board meetings
159 filed, newest first. Page 4 of 4.
Jan 2008
14 Jan · Board meeting
To consider and take on record the unaudited financial results for the third quarter and nine months ended December 31, 2007.
Oct 2007
16 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”
Jul 2007
17 Jul · Board meeting
Meeting on 27 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
25 May · Board meeting
Inter-alia to consider and take on record Audited Financial Results for the Fourth quarter and audited results for the year ended March 31, 2007.
Mar 2007
21 Mar · Board meeting
The committee constituted by the board for the purpose of allotment of warrants met at the registered office on 21-3-2007 and allotted the warrants as follows: 1) Dr.R.T.Ravi (HUF) - 12,20,000; 2) Mr. Ajay Ravi - 4,00,000; 3) Dr. T.Kuchroo - 50,000; 4) Mr. G.V.L.Prasad - 1,00,000; 5) Mr. G.Murthy Raju - 80,000; 6) Mr. Bh.Nagaraju - 80,000; 7) Mr. K. Venkateswarlu - 70,000. Total - 20,00,000. The above allotment is subject to the condition that the allottees pay the balance amount of 90% due on the value of shares within a period of 18 months from 21-3-2007 (the date of allotment of warrants) and get them converted into equal number of equity shares in the company and also subject to the regulations of SEBI applicable to preferential allotments14 Mar · Board meeting
The empowered committee of directors will be meeting at 11.00 a.m. on Wednesday 21st March, 2007 to allot the warrants to the selected persons as given in the special resolution passed by the members in the extraordinary general meeting.
Feb 2007
22 Feb · Board meeting
Board of directors, in their meeting held on February 22, 2007, have allotted 10,50,000 equity shares to M/s. Ranbaxy Laboratories Ltd., on preferential basis.14 Feb · Board meeting
In pursuance of the sanction given by the members in the extraordinary general meeting held on 7-2-2007 and having received the in-principle approval from the Bombay stock Exchange Ltd., the Board of directors will be meeting on Thursday 22nd February, 2007 to consider and allot the 10,50,000 equity shares on preferential basis to M/s Ranbaxy Laboratories Ltd".
Jan 2007
8 Jan · Board meeting
To consider and take on record the unaudited financial results for the quarter ended 31st December, 2006. The Board will also consider allotment of equity shares and warrants to promoters and others on preferential basis subject to SEBI Regulations.